Skip to main content

Table 4 Healthcare resource utilization and economic impact of incontinence

From: Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS)

  All patients Incontinence episode per day
0 1 2–3 ≥4 p-value
  N 625 162 165 177 121
Heath service utilization, mean number of visits over 6 month (SD)
Outpatient 1.42 (2.28) 1.30 (2.34) 1.35 (2.29) 1.48 (1.76) 1.61 (2.79) 0.484
  • Hospital 1.01 (1.53) 0.80 (1.38) 0.95 (1.63) 1.16 (1.44) 1.13 (1.69) 0.073
  • Clinic 0.35 (1.30) 0.48 (1.67) 0.34 (1.40) 0.24 (0.68) 0.35 (1.29) 0.152
  • Oriental clinic 0.07 (0.66) 0.03 (0.25) 0.06 (0.55) 0.07 (0.43) 0.13 (1.21) 0.289
Inpatient 0.05 (0.26) 0.06 (0.28) 0.06 (0.23) 0.03 (0.17) 0.09 (0.37) 0.736
  • Hospital 0.05(0.25) 0.05 (0.24) 0.05 (0.22) 0.03 (0.17) 0.09 (0.37) 0.537
  • Clinic 0.003 (0.06) 0.006 (0.08) 0.006 (0.08) 0 0 0.247
Emergency care 0.014 (0.13) 0.006 (0.08) 0.018 (0.13) 0.017 (0.13) 0.017 (0.18) 0.462
Incontinence pad use
  % of patients using incontinence pads 29.4 17.3 20.6 32.8 52.9 <0.0001
  Weekly cost of incontinence pads (SD) KRW 1351 (8465) KRW 227 (1032) KRW 566 (1775) KRW 863 (3014) KRW 5259 (19320) <0.0001
Work Productivity and Activity Impairment (WPAI) due to urinary incontinence
  % work time missed (SD) 2.9 (8.1) 0.6 (2.0) 1.4 (4.7) 4.2 (9.6) 7.0 (12.9) 0.001
  % regular activity impairment (SD) 29.0 (28.4) 21.2 (24.3) 26.0 (27.4) 31.5 (31.0) 44.8 (26.9) 0.001
Willingness of patients to try medical proceduresa to improve urinary symptoms
  % Willing to try 47.5 37.7 41.2 52.0 62.8 <0.0001
  1. aIncludes sacral neuromodulation, botulinum toxin injections, electrical stimulation, biofeedback training, bladder denervation, detrusor myomectomy, percutaneous tibial nerve stimulation